About a year ago, while we were still waiting for Viekira Pak from AbbVie to hit pharmacy shelves, many Gilead Sciences (NASDAQ:GILD) investors were worried the competitor would consume a hefty chunk of the overall hepatitis C market. Fast-forward to the present, and it seems those fears were overblown. Sales of Gilead’s hepatitis C franchise -- Harvoni and Sovaldi -- are rolling in at an annualized run rate of $19.2 billion. Third-quarter sales of Viekira Pak suggest an annualized run rate of “just” $1.9 billion.
